<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>190(2)</volume><submitter>Armand P</submitter><funding>Merck Sharp &amp;amp; Dohme Corp., a subsidiary of Merck &amp;amp; Co., Inc., Kenilworth, NJ, USA</funding><journal>British journal of haematology</journal><pagination>e117-e120</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7496875</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Pembrolizumab in relapsed or refractory Richter syndrome.</pubmed_title><pmcid>PMC7496875</pmcid><funding_grant_id>N/A</funding_grant_id><pubmed_authors>Christian B</pubmed_authors><pubmed_authors>Marinello P</pubmed_authors><pubmed_authors>Eichhorst B</pubmed_authors><pubmed_authors>Murawski N</pubmed_authors><pubmed_authors>Zain J</pubmed_authors><pubmed_authors>Chatterjee A</pubmed_authors><pubmed_authors>Phillips T</pubmed_authors><pubmed_authors>Stathis A</pubmed_authors><pubmed_authors>Hawkes EA</pubmed_authors><pubmed_authors>Svoboda J</pubmed_authors><pubmed_authors>Armand P</pubmed_authors><pubmed_authors>Pagel JM</pubmed_authors><pubmed_authors>Gulbas Z</pubmed_authors><pubmed_authors>Molin D</pubmed_authors><pubmed_authors>Ribrag V</pubmed_authors><pubmed_authors>Orlowski R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pembrolizumab in relapsed or refractory Richter syndrome.</name><description/><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jul</publication><modification>2025-04-04T23:03:57.687Z</modification><creation>2025-04-04T23:03:57.687Z</creation></dates><accession>S-EPMC7496875</accession><cross_references><pubmed>32544980</pubmed><doi>10.1111/bjh.16762</doi></cross_references></HashMap>